Trial of BMS-690514 in Non-Small Cell Lung Cancer Subjects Who Have Been Treated With Gefitinib or Erlotinib and Are Genotypically EGFR Mutation Positive or Who Have Had a Prior Response
The purpose of this study is to observe an improvement in overall response rate in NSCLC subjects who have been treated with gefitinib or erlotinib and are genotypically EGFR mutation positive or who have had a prior a response.
Non-Small-Cell Lung Carcinoma
DRUG: BMS-690514
To estimate objective response rate in NSCLC subjects who have been treated with gefitinib or erlotinib and are genotypically EGFR mutation positive or who have had a prior a response, Tumor assessment Day 29 and every 8 weeks from Day 1 thereafter until disease progression|To estimate objective response rate in NSCLC subjects who have been treated with gefitinib or erlotinib and are genotypically EGFR mutation positive or who have had a prior a response, Tumor assesments on Day 29 by CT or MRI|To estimate objective response rate in NSCLC subjects who have been treated with gefitinib or erlotinib and are genotypically EGFR mutation positive or who have had a prior a response, Tumor assessments every 8 weeks from Day 1 by CT or MRI
To estimate disease control rate and progression free survival in all treated subjects, Tumor assessment Day 29 and every 8 weeks from Day 1 thereafter until disease progression|To estimate disease control rate and progression free survival in all treated subjects, Tumor assessment from Day 29|To estimate disease control rate and progression free survival in all treated subjects, Tumor assessment every 8 weeks from Day 1 until disease progression|To evaluate safety and tolerability of BMS-690514 in all treated subjects, Average about 10 months
The purpose of this study is to observe an improvement in overall response rate in NSCLC subjects who have been treated with gefitinib or erlotinib and are genotypically EGFR mutation positive or who have had a prior a response.